Nothing Special   »   [go: up one dir, main page]

Willemsen et al., 2021 - Google Patents

TNF leads to mtDNA release and cGAS/STING-dependent interferon responses that support inflammatory arthritis

Willemsen et al., 2021

View HTML @Full View
Document ID
4607619597871545788
Author
Willemsen J
Neuhoff M
Hoyler T
Noir E
Tessier C
Sarret S
Thorsen T
Littlewood-Evans A
Zhang J
Hasan M
Rush J
Guerini D
Siegel R
Publication year
Publication venue
Cell reports

External Links

Snippet

Tumor necrosis factor (TNF) is a key driver of several inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, in which affected tissues show an interferon-stimulated gene signature. Here, we demonstrate that TNF triggers a …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Willemsen et al. TNF leads to mtDNA release and cGAS/STING-dependent interferon responses that support inflammatory arthritis
Orzalli et al. An antiviral branch of the IL-1 signaling pathway restricts immune-evasive virus replication
Skopelja-Gardner et al. The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent
Crow et al. Type I interferons in autoimmune disease
Bengtsson et al. Role of interferons in SLE
Karki et al. IRF8 regulates transcription of Naips for NLRC4 inflammasome activation
Severa et al. Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
Funabiki et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5
Goritzka et al. Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection
Guiducci et al. RNA recognition by human TLR8 can lead to autoimmune inflammation
Dillon et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3
Shrivastav et al. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus
Brownell et al. Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection
Fu et al. TNFR2/14-3-3ε signaling complex instructs macrophage plasticity in inflammation and autoimmunity
Lodi et al. Type I interferon–related kidney disorders
Prabakaran et al. A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology
Weiss et al. The interferon-induced exonuclease ISG20 exerts antiviral activity through upregulation of type I interferon response proteins
Schountz et al. Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus
Bhattacharya et al. Triggering ubiquitination of IFNAR 1 protects tissues from inflammatory injury
Cham et al. Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus
Lai et al. Mitochondrial CMPK2 mediates immunomodulatory and antiviral activities through IFN-dependent and IFN-independent pathways
Kakkar et al. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
Tucci et al. Immature dendritic cells in multiple myeloma are prone to osteoclast‐like differentiation through interleukin‐17 A stimulation
Harvey et al. The transcriptomic response of rat hepatic stellate cells to endotoxin: implications for hepatic inflammation and immune regulation
Ponia et al. Mitophagy antagonism by ZIKV reveals Ajuba as a regulator of PINK1 signaling, PKR-dependent inflammation, and viral invasion of tissues